Appraisals - ASAR & FAR
- 01/08/2019
- Appraisal Report: azithromycin (Zedbac) 2476
-
-
- 31/07/2019
- Appraisal Report: avanafil (Spedra) 1261
-
-
- 27/08/2019
- Appraisal Report: atazanavir (Reyataz) 746
-
-
- 01/08/2019
- Appraisal Report: alogliptin (Vipidia) 857
-
-
- 31/07/2019
- Appraisal Report: aflibercept (Eylea) 1586
-
-
- 19/08/2019
- Appraisal Report: adalimumab (Humira) 8
-
-
- 01/08/2019
- Appraisal Report: adalimumab (Humira) 2571
-
-
- 03/02/2020
- Appraisal Report: adalimumab (Humira) 2562
-
-
- 08/08/2019
- Appraisal Report: adalimumab (Humira) 1977
-
-
- 08/08/2019
- Appraisal Report: adalimumab (Humira) 1381
-
-
- 19/08/2019
- Appraisal Report: abiraterone (Zytiga) 3
-
-
- 03/02/2020
- Appraisal Report: abatacept (Orencia) 2
-
-
- 26/02/2020
- Appraisal Report: vismodegib (Erivedge) 1037
-
-